Erbitux Soln For Inf


Indications and Reactions:

Role Indications Reactions
Primary
Colorectal Cancer Metastatic 28.5%
Premedication 16.9%
Colon Cancer 10.7%
Colon Cancer Metastatic 6.8%
Head And Neck Cancer 5.9%
Colorectal Cancer 5.5%
Hypertension 3.9%
Chemotherapy 3.2%
Squamous Cell Carcinoma Of Head And Neck 2.7%
Tongue Neoplasm Malignant Stage Unspecified 2.7%
Rectal Cancer 2.1%
Pain 1.8%
Adenocarcinoma Of Colon 1.6%
Prophylaxis Of Nausea And Vomiting 1.6%
Colon Cancer Stage Iv 1.1%
Neuralgia 1.1%
Prophylaxis 1.1%
Adenocarcinoma 0.9%
Gastrooesophageal Cancer 0.9%
Lip And/or Oral Cavity Cancer 0.9%
Infusion Related Reaction 14.7%
Rash 11.8%
Rash Pustular 7.4%
Anaphylactic Reaction 5.9%
Hypotension 5.9%
Vomiting 5.9%
Febrile Neutropenia 4.4%
Hypersensitivity 4.4%
Ileus 4.4%
Myocardial Infarction 4.4%
Weight Decreased 4.4%
Acute Respiratory Distress Syndrome 2.9%
Bone Pain 2.9%
General Physical Health Deterioration 2.9%
Haematuria 2.9%
Headache 2.9%
Hyperthermia 2.9%
Neurosensory Hypoacusis 2.9%
Oedema Peripheral 2.9%
Pancytopenia 2.9%
Secondary
Neuralgia 21.7%
Tongue Neoplasm Malignant Stage Unspecified 13.0%
Lung Neoplasm Malignant 8.7%
Pain 8.7%
Premedication 8.7%
Throat Cancer 8.7%
Chemotherapy 4.3%
Hypopharyngeal Cancer 4.3%
Nausea 4.3%
Oesophageal Carcinoma 4.3%
Prophylaxis 4.3%
Squamous Cell Carcinoma Of The Oral Cavity 4.3%
Tonsil Cancer 4.3%
Rash Papular 50.0%
Anaphylactic Reaction 16.7%
Headache 16.7%
Uveitis 16.7%

Drug Data